February 22, 2024

Grand Depart

Experienced In Technology

7 ways to enhance healthcare

6 min read
7 ways to enhance healthcare
Pixabay image of a digital looking person with brain and skeleton and digital looking stuff to represent artificial intelligence or AI used in medtech and healthcare

[Image from Pixabay]

Whether it’s OpenAI’s ChatGPT or Microsoft’s new Bing, 2023 is the year when generative artificial intelligence entered the popular consciousness.

In the medtech space, it seems as though every company is seeking ways to incorporate some form of AI into the digital features of their products and services.

So what is artificial intelligence good at when it comes to advancing medtech and healthcare in general? Here are seven recent examples:

1. Helping physicians quickly identify medical problems

Marketing image shows a colonoscopy image with and without the GI Genius distributed by Medtronic that leverages AI

GI Genius’ AI-based enhancements place green boxes around areas that may need extra scrutiny during a colonoscopy, helping to prevent physicians from losing their focus. [Image courtesy of Medtronic]

Interest is growing in artificial intelligence that can help radiologists, gastroenterologists and others better spot potential diseases in the countless images they examine each day.

For example, GI Genius is an AI-assisted colonoscopy tool designed to help detect polyps that may lead to colorectal cancer. Medtronic is the exclusive worldwide distributor of the technology, which was developed and manufactured by Cosmo Pharmaceuticals. Giovanni Di Napoli, president of the gastrointestinal business at Medtronic, showed some GI Genius footage at our DeviceTalks West event in Santa Clara, California, this past October. Historically, gastroenterologists detected fewer lesions while performing colonoscopies as their day progressed from morning through the afternoon. GI Genius’ AI-based enhancements help physicians stay focused by placing green boxes around areas that may need extra scrutiny during the diagnostic imaging procedure.

GI Genius could soon get even better. Medtronic has partnered with Nvidia to enhance the tool’s AI capabilities, allowing third-party developers to train and validate their AI models using the GI Genius AI Access platform. This technology has the potential to improve patient outcomes and reduce medical variability, while transforming the way healthcare approaches the early detection of colorectal cancer.

In other recent news, Viz.ai secured FDA clearance for its artificial intelligence-powered algorithm designed to detect and triage care for suspected abdominal aortic aneurysms (AAAs). Viz AAA automatically analyzes computed tomography angiography (CTA) scans for suspected AAAs. It alerts clinicians, displaying patient scans on their mobile devices for real-time communication among specialists. Jayme Strauss, chief clinical officer at Viz.ai, thinks Viz AAA will enable care teams to prevent aortic rupture and other catastrophic aortic emergencies by increasing surveillance. Viz.ai plans to continue expanding its healthcare offerings.

Meanwhile, HeartBeam recently secured a pivotal patent related to artificial intelligence capabilities for its AIMIGo system — a personal, portable vector electrocardiogram (VECG) system. HeartBeam is now partnering with Samsung to boost cardiac diagnostics.

2. Enabling better and more discreet health monitoring

Sensydia marketing image of the biosensor array in its AI-powered Cardiac Performance System (CPS)

Sensydia’s AI-powered Cardiac Performance System (CPS) uses ultra-sensitive biosensors for the rapid, non-invasive measurement of a number of cardiac metrics. [Image courtesy of Sensydia]

It is hard these days to find a digital health or health monitoring company that is not talking about incorporating artificial intelligence into its offerings. AI has the potential to enable more discreet sensor arrays. The result is that doctors and patients can gain insights from the monitoring with minimal hassle. For example, Sensydia, which has undertaken multiple clinical studies, recently completed enrollment in a 225-subject development study for its AI-powered Cardiac Performance System (CPS). The Los Angeles–based company designed the noninvasive CPS device to analyze heart sound and provide physicians with a full cardiac assessment of patients in under 5 minutes. The CPS device may enable earlier detection and improved therapy guidance for heart failure and pulmonary hypertension patients.

The CPS uses ultra-sensitive biosensors for the rapid, non-invasive measurement of a number of cardiac metrics, such as ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure. Traditionally, patients need echocardiography and invasive catheterization to obtain these measurements, according to the company.

Sensydia announced in early May that it has raised an additional $8 million from an expanded syndicate of investors. The company plans to submit to the FDA in 2024 for prioritized review as part of the agency’s Breakthrough Devices Program.

Meanwhile, Boston-based Biofourmis has AI-driven software to collect and analyze patient data in real-time to identify shifts that require proactive interventions. It partnered with Japanese pharma giant Chugai to objectively measure pain in women with endometriosis. Their strategy is to use a biosensor and an AI-based algorithm utilizing Biofourmis’ Biovitals.

3. AI-enabled prosthetics

Ottobock marketing image of its Myo Plus AI pattern recognition system for prosthetics users

The Myo Plus system [Image courtesy of Ottobock]

Advanced AI algorithms hold promise to better enable people to use myoelectric control — involving discreet electric signals from their muscles — to control robotic prosthetics.

For example, Ottobock has its Myo Plus pattern recognition system for trans-radial users. Myo Plus is meant to allow the system to adjust to natural movements versus requiring the user to adapt to the system.

4. Better visualization during surgery

Activ Surgical announced in January that it completed the first AI-enabled surgery using its ActivSight Intelligent Light product. Designed to provide enhanced visualization and real-time, on-demand surgical insights in the operating room, the ActivSight model attaches to laparoscopic and robotic systems and integrates with standard monitors. The first AI-enabled ActivSight surgery took place on Dec. 22, 2022, at the Ohio State University Wexner Medical Center. Dr. Matthew Kalady performed a laparoscopic left colectomy using the colorectal AI mode within ActivSight. The company says its goal is for every surgical imaging system to deliver intelligent information, reducing surgical complication rates.

Activ Surgical image of its Activ Sight system that uses AI

The Activ Sight system [Image courtesy of Activ Surgical]

“While using one of ActivSight’s intraoperative visual overlays, the dye-free ActivPerfusion Mode, I was able to clearly see key critical structures in the surgical site and tissue perfusion in real-time,” Kalady said in a news release. “With the press of a button, the colorectal AI mode was enabled, removing distractions of background signals from non-bowel tissue and clearly focusing on perfusion to the colon. There was a clear difference in visualization during AI mode.”

5. Improved data collection from medical settings

A surgeon using the Proprio Paradigm system to visualize a spine surgery.

Proprio designed its Paradigm system to help surgeons better visualize spinal surgeries. [Photo courtesy of Proprio]

Artificial intelligence could help with surgical data collection. A case in point is Proprio, which is rolling its AI-powered surgical navigation system into operating rooms to collect data. The idea is that the data will ultimately help surgeons improve how they perform procedures. The Seattle-based startup said it has placed its Paradigm visualization and navigation system in several U.S. operating rooms to capture surgical data that will be useful for accelerating the system’s development.

Proprio announced FDA clearance of the Paradigm system in late April.

6. Making better sense of patient data

GE HealthCare last year unveiled its Edison Digital Health Platform, an AI-powered, vendor-agnostic hosting and data aggregation platform. The medtech giant said the aim of the platform is to enable the easy deployment of clinical, workflow, analytics, and AI tools, connecting devices and other data sources into an aggregated clinical data layer. The open and published interfaces on Edison support the integration of healthcare providers and third-party developers’ applications into existing workflows. GE HealthCare had plans to integrate and deploy its own apps onto the platform. A company official said the goal was for clinicians to have actionable insights at their fingertips to help better serve their patients.

7. The ability to crack tough scientific problems — and enable countless innovations

DeepMind marketing image of protein structures deciphered by its AlphaFold AI

DeepMind’s AlphaFold artificial intelligence predicted the structure of more than 200 million proteins. [Image courtesy of DeepMind]

DeepMind, which has the same parent company as Google, has an artificial intelligence system called AlphaFold that cracked an extremely difficult scientific problem. It predicted the structure of more than 200 million proteins, which represent almost every known cataloged protein. AlphaFold and the European Bioinformatics Institute have expanded the database by more than 200-fold to over 200 million predicted structures. As our fellow WTWH Media site Drug Discovery & Development reported last year, AlphaFold is capable of making it possible to search for the 3D structure of proteins almost as easily as doing a keyword Google search. It has also made the data freely available to users for any purpose. Applications of the AI system include accelerating the discovery of drugs for neglected diseases, combating antibiotic resistance, studying the nuclear pore complex, developing a novel malaria vaccine, shedding light on genetic variation, gauging the impact of rotavirus on gastroenteritis, and contributing to drug development for cancer and neurological disease.

This story originally ran on March 24, 2023. Updated on May 30, 2023.

Leave a Reply

Copyright © All rights reserved. | Newsphere by AF themes.
x